Market Overview

AcelRx Announces Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System Meets Primary End-Point

AcelRx Pharmaceuticals (NASDAQ: ACRX) announced today it had met the primary endpoint in the Phase 3 non-inferiority study of the sublingual Sufentanil NanoTab PCA System vs. IV PCA with morphine. The top-line data is expected to be released prior to market opening on November 15, 2012, and following such release AcelRx management will host an investment-community conference call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss the Phase 3 top-line results.

See full press release

Posted-In: News Guidance Asset Sales Management Stock Split M&A Global

 

Most Popular

Related Articles (ACRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters